Drug Development

Clinical Trials Regulatory Approval Market Competition Market Launches Pharmaceutical Research Market Trends Oncology Clinical Research FDA Approval Biosimilars

Gilead to Buy Ouro Medicines as Galapagos Enters Talks to Share Costs

The potential pact would spread financial risk while advancing a novel T cell therapy for autoimmune disease.

Immutep Halts Phase III Lung Cancer Trial After Futility Call as Shares Crash

Astellas–Vir Prostate Cancer Alliance Launches With New Data as VIR Stock Surges

Pfizer to Commercialize Sciwind’s GLP-1 Ecnoglutide in China Under Exclusive License

Barclays Starts Merck at Overweight on 2026 Pipeline Catalysts as WSJ Reports Business Split Plan

FDA Approves Vanda’s Bysanti for Bipolar I Mania and Schizophrenia

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

Zydus to Pay $120 Million to Settle Astellas Mirabegron Patent Case, Continue U.S. Generic Sales

Takeda Strikes Multi-Year AI Drug Discovery Pact With Iambic Worth Over $1.7 Billion

Novo Nordisk Sees Up to 13% Drop in 2026 Profit and Sales After 'Unprecedented' U.S. Price Squeeze

Mankind Pharma’s Q3 Profit Climbs on Chronic-Drug Demand as Shares Slide on Margin Concerns

Novo Nordisk’s Oral Wegovy Debuts With Strong Prescriptions as BMO Stays Cautious

Lilly Signs Up to $1.12 Billion Gene-Editing Pact to Tackle Hearing Loss

Insilico Medicine Surges on Hong Kong Debut After HK$2.3 Billion IPO

Prolynx Raises $70 Million to Advance Ultra-Long-Acting Obesity Drugs

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

Praxis Relutrigine Study Halted Early for Efficacy as FDA Review Meeting Set

Gilead Starts Shipping Twice-Yearly HIV Prevention Shot to Eswatini and Zambia

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Lilly's Rally Deepens as U.S. Access Deal Recasts Outlook for GLP‑1 Drugs